VERU INC. Increase Decrease In Operating Lease Liability
VERU INC. (VERU) reported Increase Decrease In Operating Lease Liability of -$434.07 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- VERU INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$150.45K.
- VERU INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$144.01K.
- VERU INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$139.61K.
- VERU INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$137.17K.
- VERU INC. increase decrease in operating lease liability for fiscal 2025 was -$625.35K.
- VERU INC. increase decrease in operating lease liability for fiscal 2024 was -$683.83K.
- VERU INC. increase decrease in operating lease liability for fiscal 2023 was -$666.86K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$150.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | -$294.46K derived: sum of 2 quarters · filed 2026-08-10 | -$434.07K 10-Q · filed 2026-08-10 | -$571.25K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$144.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$283.62K 10-Q · filed 2026-05-13 | -$420.79K derived: sum of 3 quarters · filed 2026-05-13 | -$555.57K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$139.61K 10-Q · filed 2026-02-11 | -$276.78K derived: sum of 2 quarters · filed 2026-02-11 | -$411.56K derived: sum of 3 quarters · filed 2026-08-10 | -$540.28K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-09-30 | -$137.17K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -$271.95K derived: sum of 2 quarters · filed 2026-08-10 | -$400.68K derived: sum of 3 quarters · filed 2026-08-10 | -$625.35K 10-K · filed 2025-12-17 |
| 2025-06-30 | -$134.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | -$263.50K derived: sum of 2 quarters · filed 2026-08-10 | -$488.18K 10-Q · filed 2026-08-10 | -$614.82K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$128.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$353.40K 10-Q · filed 2026-05-13 | -$480.04K derived: sum of 3 quarters · filed 2026-05-13 | -$672.37K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$224.68K 10-Q · filed 2026-02-11 | -$351.31K derived: sum of 2 quarters · filed 2026-02-11 | -$543.65K derived: sum of 3 quarters · filed 2026-02-11 | -$737.57K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | -$126.64K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -$318.97K derived: sum of 2 quarters · filed 2025-12-17 | -$512.89K derived: sum of 3 quarters · filed 2025-12-17 | -$683.83K 10-K · filed 2025-12-17 |
| 2024-06-30 | -$192.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | -$386.25K derived: sum of 2 quarters · filed 2025-08-12 | -$557.19K 10-Q · filed 2025-08-12 | -$770.24K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$193.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-08 | -$364.86K 10-Q · filed 2025-05-08 | -$577.91K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$170.93K 10-Q · filed 2025-02-13 | -$383.99K derived: sum of 2 quarters · filed 2025-02-13 | ||
| 2023-09-30 | -$213.05K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | -$666.86K 10-K · filed 2024-12-16 | ||
| 2023-06-30 | -$453.81K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |